Han-Qing Ye

Han-Qing Ye

Auto-generated profile, based on publicly available information

Han-Qing Ye

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Emerging Microbes & Infections
Verified
Journal Article
Open access
YZYa-Nan Zhang
Ya-Nan Zhang
QZQiu-Yan Zhang
Qiu-Yan Zhang
XLXiao-Dan Li
Xiao-Dan Li
JXJin Xiong
Jin Xiong
SXShu-Qi Xiao
Shu-Qi Xiao
BZBo Zhang
Bo Zhang
The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.

1 October 2020 in Antiviral Research
Verified
Journal Article
Closed access
ZZZhe-Rui Zhang
Zhe-Rui Zhang
HZHong-Qing Zhang
Hong-Qing Zhang
XLXiao-Dan Li
Xiao-Dan Li
CDCheng-Lin Deng
Cheng-Lin Deng
ZWZhen Wang
Zhen Wang
HYHan-Qing Ye
Han-Qing Ye

3 October 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZZZhe-Rui Zhang
Zhe-Rui Zhang
YZYa-Nan Zhang
Ya-Nan Zhang
XLXiao-Dan Li
Xiao-Dan Li
HZHong-Qing Zhang
Hong-Qing Zhang
SXShu-Qi Xiao
Shu-Qi Xiao
BZBo Zhang
Bo Zhang
Dear Editor, Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly and developed into a global pandemic since its outbreak in December 2019. Currently, there is no antiviral treatment available for human use. Numerous compounds, such as remdesivir and chloroquine, have been reported to inhibit SARS-CoV-2 replication effectively in vitro, but for most of them, the in vivo efficacies against SARS-CoV-2 are still under clinical studies, and for chloroquine, a drug with prominent in vitro antiviral activity, it has been found no beneficial effect for COVID-19 patients in the recent largest study. It is thus urgent to speed up large-scale screening to discover drug candidates to treat COVID-19. Recently, several high throughput screening (HTS) assays had been developed for SARS-CoV-2 antiviral discovery. A virtual screening and a fluorogenic protease enzymatic assay based on the main protease of SARS-CoV-2 have been established to screen the protease inhibitors. A reporter gene system had been developed to screen inhibitors targeting the-1 ribosomal frameshifting of SARS-CoV-2. 1 These systems select the inhibitors targeting to one specific step during infection. Here, we established a cytopathic effect (CPE)-based HTS assay in Vero-E6 cells that are permissive to SARS-CoV-2 infection to screen for inhibitors aiming to the entire viral life cyle. The antiviral efficacy of compounds was determined by the reduction of CPE, which was quantified by measuring cell viability using CCK-8 assay. The HTS conditions, including the cell density, the multiplicity of infection (MOI) and the time of incubation were first optimized in a 96-well format. The final HTS conditions were at 5000 cells/well, 0.01 of MOI, 48 h of incubation to achieve maximum assay sensitivity (producing consistently > 90% CPE in the Vero-E6 cells at endpoint) for drug screening (Supplementary Fig. S1a and Fig. 1a). Multiple known inhibitors, including remdesivir, chloroquine, neutralizing human antibody CB6 2 and IFN-α were used as positive controls to validate the availability of the CPE-based HTS assay. Consistent with previous results, all these reagents provided protection against SARS-CoV-2 infection, and the Z′ values were 0.68, 0.56, 0.66, and 0.58, respectively (HTS assays with Z′ ≥ 0.5 are considered robust) (Supplementary Fig. S1b). These results demonstrated that this CPE-based HTS assay is reliable and robust for screening inhibitors of SARS-CoV-2. As the compound is usually dissolved in DMSO, we also tested the effect of different concentrations of DMSO on SARS-CoV-2 replication to determine the optimal solvent concentration for the assay. As shown in supplementary Fig. S1c, DMSO had no effect on cell viability at ≤1% (v/v) concentration. Therefore, we chose 0.25% DMSO as the working concentration to dissolve the compounds. To further verify the reliability of the selected conditions, we evaluated the inhibitory effects of different concentrations of chloroquine on SARS-CoV-2 infection under the above HTS

1 February 2018 in Antiviral Research
Verified
Journal Article
Closed access
JLJia-Qi Li
Jia-Qi Li
CDCheng-Lin Deng
Cheng-Lin Deng
DGDayong Gu
Dayong Gu
XLXiao Li
Xiao Li
LSLei Shi
Lei Shi
HYHan-Qing Ye
Han-Qing Ye

1 May 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JWJiqin Wu
Jiqin Wu
HYHan-Qing Ye
Han-Qing Ye
QZQiu-Yan Zhang
Qiu-Yan Zhang
GLGuoliang Lu
Guoliang Lu
BZBo Zhang
Bo Zhang
PGPeng Gong
Peng Gong
The flaviviruses pose serious threats to human health. Being a natural fusion of a methyltransferase (MTase) and an RNA-dependent RNA polymerase (RdRP), NS5 is the most conserved flavivirus protein and an important antiviral target. Previously reported NS5 structures represented by those from the Japanese encephalitis virus (JEV) and Dengue virus serotype 3 (DENV3) exhibit two apparently different global conformations, defining two sets of intra-molecular MTase-RdRP interactions. However, whether these NS5 conformations are conserved in flaviviruses and their specific functions remain elusive. Here we report two forms of DENV serotype 2 (DENV2) NS5 crystal structures representing two conformational states with defined analogies to the JEV-mode and DENV3-mode conformations, respectively, demonstrating the conservation of both conformation modes and providing clues for how different conformational states may be interconnected. Data from in vitro polymerase assays further demonstrate that perturbing the JEV-mode but not the DENV3-mode intra-molecular interactions inhibits catalysis only at initiation, while the cell-based virological analysis suggests that both modes of interactions are important for virus proliferation. Our work highlights the role of MTase as a unique intra-molecular initiation factor specifically only through the JEV-mode conformation, providing an example of conformation-based crosstalk between naturally fused protein functional modules. The function of a protein is often dictated by a single defined fold, which in turn is determined by its amino acid sequences. However, multiple global conformations can be utilized by a protein to fulfill distinct functions under different circumstances. The flavivirus NS5 protein, a natural fusion of a N-terminal methyltransferase (MTase) and a C-terminal RNA-dependent RNA polymerase (RdRP), may be such an example. Previously reported NS5 crystal structures exhibit two apparently different global conformations. In this work, we demonstrate that both conformations are conserved in the flaviviruses and important for virus proliferation, but only one of them is clearly relevant to RdRP catalysis, in particular at the early stages of the RNA synthesis.

25 October 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JLJia-Qi Li
Jia-Qi Li
ZZZhe-Rui Zhang
Zhe-Rui Zhang
HZHong-Qing Zhang
Hong-Qing Zhang
YZYa-Nan Zhang
Ya-Nan Zhang
XZXiang-Yue Zeng
Xiang-Yue Zeng
HYHan-Qing Ye
Han-Qing Ye
The lung is the prophylaxis target against SARS-CoV-2 infection, and neutralizing antibodies are a leading class of biological products against various infectious viral pathogen. In this study, we develop a safe and cost-effective platform to express neutralizing antibody in the lung with replicating mRNA basing on alphavirus replicon particle (VRP) delivery system, to prevent SARS-CoV-2 infections. First, a modified VEEV replicon with two subgenomic (sg) promoters was engineered to translate the light and heavy chains of antibody simultaneously, for expression and assembly of neutralizing anti-SARS-CoV-2 antibody CB6. Second, the feasibility and protective efficacy of replicating mRNA against SARS-CoV-2 infection were demonstrated through both in vitro and in vivo assays. The lung target delivery with the help of VRP system resulted in efficiently block SARS-CoV-2 infection with reducing viral titer and less tissue damage in the lung of mice. Overall, our data suggests that expressing neutralizing antibodies in the lungs with the help of self-replicating mRNA could potentially be a promising prophylaxis approach against SARS-CoV-2 infection.